Table 1 Distribution of the clinico-pathological factors of the study participants.
Characteristics | Frequency (%) |
|---|---|
Time since diagnosis (months) | |
Median (IQR) | 48 (24–84) |
Minimum - maximum | (12–180) |
Type of Surgery | |
MRM | 79 (52.7) |
BCS | 71 (47.3) |
Laterality | |
Right | 84 (56.0) |
Left | 66 (44.0) |
Histological type | |
IDC | 130 (86.7) |
ILC | 20 (13.3) |
Histological grade | |
I | 3 (2.0) |
II | 128 (85.3) |
III | 19 (12.7) |
ER | |
Positive | 129 (86.0) |
Negative | 21 (14.0) |
PR | |
Positive | 116 (77.3) |
Negative | 34 (22.7) |
HER2 | |
Positive | 28 (18.7) |
Negative | 122 (81.3) |
Lymph Node status | |
Positive | 89 (59.3) |
Negative | 61 (40.7) |
Total number of disected LN | |
≤10 | 65 (43.3) |
> 10 | 85 (56.7) |
Subtype | |
HR+/HER2− | 108 (72.0) |
HR+/HER+ | 22 (14.7) |
HR−/HER+ | 6 (4.0) |
HR−/HER− | 14 (9.3) |
AJCC Stage | |
Stage I | 11 (7.3) |
Stage II | 97 (64.7) |
Stage III | 42 (28.0) |
Type of Adjuvant Therapy | |
Chemotherapy | 86 (59.3) |
Radiotherapy | 89 (59.3) |
Hormonal Therapy | 119 (79.3) |
Targeted Therapy | 24 (16.0) |